BioLife Solutions, Inc. reaffirmed earnings guidance for the fiscal 2023. For the period, the company expected revenue to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.87 USD | +0.53% | -2.91% | +28.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.34% | 956M | |
-2.51% | 181B | |
+2.07% | 108B | |
-0.63% | 69.41B | |
+14.99% | 46.61B | |
-7.34% | 45.85B | |
+7.97% | 42.61B | |
+17.77% | 30.71B | |
+16.92% | 25.63B | |
-6.63% | 23.32B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023